r.iyer98/100
Support answered on a Sunday, correctly, with the batch record attached. That is well beyond what I expected.
CPC — Chinese Peptide Company Co., Ltd.
Hangzhou, CN · established 2001. The index holds 309 assay reports across 52 batches and 32 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where CPC sells
Chinese Peptide Company Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit CPC at chinesepeptidecompany.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Chinese Peptide Company Co., Ltd.
- Short code in this index
- CPC
- Also known as
- CPC · CPC Biotech · Chinese Peptide Company
- City
- Hangzhou
- Region
- Hangzhou
- Country
- CN
- Established
- 2001
- First record in index
- 24 Jan 2024
- Most recent record
- 11 Oct 2026
Block 1b
Dispatch and warehouses
Where the supplier holds regional stock. Material assayed by the index is dispatched from these locations, not from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.28%
n=295
Interquartile range
0.96pp
n=295
10th percentile
97.32%
n=295
Pass rate vs index spec
56.9%
n=295
Median recovery vs claim
97.8%
n=174
Median water
5.41%
n=309
Median |mass error|
2.3ppm
n=254
Records carrying a flag
80.6%
n=309
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
1.02pp
n=34
Index median spread
0.95pp
n=20
Lots tested 3+ times
34
n=52
Across the 34 CPC lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 1.02 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.29pp
n=51
Index median divergence
+0.31pp
n=20
Divergences in the supplier's favour
76%
n=51
Divergences beyond 1 pp
4%
n=51
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
97.93%
n=66
Supplier-supplied median
98.51%
n=209
Supplier-supplied share of records
69.9%
n=309
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of CPC batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
68/100
n=52
Index median score
79/100
n=20
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 98% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 60% | 25 points | |
| Peptide content stated | 40% | 20 points | |
| Endotoxin stated | 19% | 15 points | |
| Named impurities rather than a total | 21% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| BPC-157 | Tissue-repair | 30 | 98.48 | 99.15 | -0.67 | 98.0 | 73 |
| Semaglutide | Incretin | 25 | 97.88 | 98.87 | -0.99 | 97.0 | 96 |
| TB-500 | Tissue-repair | 25 | 98.96 | 99.47 | -0.51 | 98.5 | 60 |
| CJC-1295 (no DAC) | Growth-hormone | 22 | 97.65 | 98.61 | -0.96 | 98.0 | 18 |
| Tirzepatide | Incretin | 19 | 96.89 | 98.44 | -1.55 | 97.0 | 42 |
| Ipamorelin | Growth-hormone | 14 | 98.10 | 99.48 | -1.38 | 99.0 | 21 |
| Thymalin | Short | 14 | n<3 | — | — | 99.0 | — |
| Pinealon | Short | 14 | 99.16 | 99.24 | -0.08 | 99.0 | 79 |
| Hexarelin | Growth-hormone | 13 | 98.58 | 98.72 | -0.14 | 99.0 | 0 |
| GHRP-6 | Growth-hormone | 13 | 99.65 | 99.65 | 0.00 | 99.0 | 100 |
| Selank | Neuroactive | 13 | 98.76 | 99.13 | -0.37 | 99.0 | 31 |
| IGF-1 LR3 | Growth-hormone | 12 | 97.73 | 97.75 | -0.02 | 95.0 | 100 |
| L-Carnosine | Short | 9 | 98.24 | 99.07 | -0.83 | 99.0 | 22 |
| L-Glutathione (reduced) | Short | 9 | 98.28 | 99.00 | -0.72 | 98.5 | 44 |
| KPV | Tissue-repair | 9 | 98.26 | 99.21 | -0.95 | 99.0 | 0 |
| Kisspeptin-10 | Melanocortin-receptor | 9 | 98.21 | 99.27 | -1.06 | 98.5 | 22 |
| Liraglutide | Incretin | 8 | 97.68 | 99.02 | -1.33 | 97.5 | 63 |
| Pemvidutide | Incretin | 8 | 98.35 | 98.41 | -0.06 | 96.0 | 100 |
| Enclomiphene citrate | Non-peptide | 7 n=7 | 98.57 | 99.23 | -0.66 | 98.5 | 57 |
| Melanotan II | Melanocortin-receptor | 6 n=6 | 99.07 | 99.24 | -0.17 | 98.5 | 100 |
| Gonadorelin | Hypothalamic | 5 n=5 | 98.66 | 99.28 | -0.62 | 98.5 | 80 |
| Thymosin α1 | Tissue-repair | 5 n=5 | 97.94 | 99.11 | -1.17 | 97.5 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 5 n=5 | 98.16 | 99.37 | -1.21 | 98.5 | 40 |
| N-Acetyl Semax Amide | Neuroactive | 2 n=2 | n<3 | 99.26 | — | 98.5 | 100 |
| GHK-Cu | Tissue-repair | 2 n=2 | n<3 | 98.54 | — | 97.0 | 100 |
| Retatrutide | Incretin | 2 n=2 | n<3 | 98.41 | — | 96.5 | 50 |
| SS-31 (Elamipretide) | Metabolic | 2 n=2 | n<3 | 99.42 | — | 98.5 | 0 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 2 n=2 | n<3 | 99.31 | — | 98.5 | 100 |
| Adipotide | Metabolic | 2 n=2 | n<3 | 98.59 | — | 96.0 | 100 |
| Triptorelin | Hypothalamic | 1 n=1 | n<3 | 98.47 | — | 98.5 | 0 |
| Sermorelin | Growth-hormone | 1 n=1 | n<3 | 98.94 | — | 98.0 | 100 |
| Semax | Neuroactive | 1 n=1 | n<3 | 99.17 | — | 98.5 | 0 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 10 | 97.52 | 96.82–98.23 | 9 |
| 2024-Q2 | 2 | 15 | 99.19 | 98.53–99.77 | 15 |
| 2024-Q3 | 2 | 4 | 99.71 | 98.74–99.93 | 3 |
| 2024-Q4 | 1 | 9 | 98.21 | 97.89–98.90 | 9 |
| 2025-Q1 | 3 | 28 | 97.92 | 97.34–99.37 | 14 |
| 2025-Q2 | 6 | 35 | 98.96 | 97.17–99.93 | 22 |
| 2025-Q3 | 10 | 51 | 98.26 | 96.72–99.72 | 43 |
| 2025-Q4 | 5 | 36 | 98.35 | 96.96–99.93 | 36 |
| 2026-Q1 | 4 | 32 | 98.47 | 97.41–99.49 | 23 |
| 2026-Q2 | 11 | 49 | 98.31 | 96.19–99.19 | 37 |
| 2026-Q3 | 6 | 40 | 97.68 | 95.92–99.39 | 38 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 143 | 98.23 | +0.00 | 98.23 |
| PeptideMeter | 51 | 98.35 | -0.05 | 98.40 |
| Medutest | 44 | 98.55 | +0.08 | 98.47 |
| VendorInvestigate | 36 | 97.95 | -0.11 | 98.06 |
| Nordanalyt | 24 | 98.51 | +0.02 | 98.49 |
| Kestrel | 11 | 98.63 | +0.24 | 98.39 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
97.0/ 100565 ratings across the index network
an.restrepo98/100
Cold pack was still hard on arrival in Dublin on day 5. My logger never went above 4°C across the whole run.
n.fontaine98/100
One of the few places that will quote hexarelin 5 mg at all, and the synthesis came back clean on an independent check.
ka.marchand94/100
Shipped from their warehouse in the Netherlands, arrived day 2, documentation complete.
f.aalto94/100
Documentation is complete and the numbers are steady. A dependable choice for routine work.
h.nakamura98/100
The certificate for lot CPC-26-613 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
j.ostergaard98/100
Asked them to hold an order until I confirmed a lot number and they did, without fuss and without a restocking charge.
a.hovland94/100
Consistent rather than flashy. Everything lands in the high nineties, and it lands there every time.
b.delgado98/100
3 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
a.bergstrom98/100
First order, deliberately small, survodutide 5 mg only. Documentation, transit and a VendorInvestigate result at 98.5% all checked out, so the next one will not be small.
v.tulloch98/100
Pleased to find they hold stock in the United Kingdom. Domestic dispatch, day 4, no customs step at all.
p.salgado98/100
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
so.broberg98/100
VendorInvestigate has now seen 5 of their lots through me. Not one has come back outside spec.
k.hovland98/100
Shipped with a stated storage recommendation and a shelf-life figure tied to it, without my asking.
d.oyelaran94/100
Everything about the order was routine in the best sense — quoted 3 days, arrived in 2.
r.yilmaz94/100
Straightforward order, arrived as described, documentation adequate and complete. Nothing to add, which is the point.
el.halonen98/100
Their raw material tested 99.2% against a reseller vial of nominally the same compound at 99.0%. Going direct is the whole argument.
n.trevino94/100
Ordered survodutide 5 mg twice. Both vials reconstituted cleanly and both matched their certificates.
so.demir94/100
Good communication throughout, accurate lead time, and the parcel arrived on day 3.
s.aalto98/100
Quoted 3 days, arrived in 2. Tracking updated at every hop from dispatch to door.
vi.sjoberg94/100
Sensible packing, sensible timelines, and a certificate that says what it should. No notes.
s.nkemelu98/100
Costed them per mg against three other suppliers on the same epithalon 10 mg spec. Competitive on price and clearly ahead on documentation.
ay.ibarra98/100
Submitted the LL-37 5 mg to Janoshik blind, without telling them the source. 99.4% against a stated 99.0%. The number holds up when nobody knows whose vial it is.
p.kravchenko98/100
Regional stock makes the difference — dispatched within the United States, day 3, cold pack still hard on arrival.
i.steiner98/100
Their warehouse in Canada had the tirzepatide 10 mg in stock and it shipped the same afternoon. Tracking never left the country.
z.ivaturi98/100
Reconstituted the sermorelin 5 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.
Block 12